Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 16 Apr 21 EFFECT Notice of effectiveness
- 16 Apr 21 424B4 Prospectus supplement with pricing info
- 15 Apr 21 S-1/A IPO registration (amended)
-
12 Apr 21 S-1/A IPO registration (amended)
- 22 Mar 21 S-1 IPO registration
RXRX similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption “Experts” and to the use of our report dated March 3, 2021 (except for paragraphs two through four of Note 16, as to which the date is April 11, 2021), in Amendment No. 1 to the Registration Statement (Form S-1 No. 333-254576) and related Prospectus of Recursion Pharmaceuticals, Inc. for the registration of shares of its Class A Common Stock.
/s/ Ernst & Young LLP
Salt Lake City, Utah
April 11, 2021